#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Gestational trophoblastic tumour Haemophagocytic lymphohistiocytosis Scleroderma associated digital ulcer Factor IX deficiency Cardiac amyloidosis Antiphospholipid antibodies Emphysema Anti-myelin-associated glycoprotein associated polyneuropathy Retinal artery occlusion Corneal neovascularisation Anal squamous cell carcinoma Rhabdoid tumour Pelizaeus-Merzbacher disease Mucopolysaccharidosis I Ischaemic stroke More trials…

    Learn about Rare Diseases

    Gaucher’s disease type I – Life with Disease Krabbe’s disease – Basic Information Paraneoplastic neurological syndrome – Diagnostics Ornithine transcarbamoylase deficiency – Trials in Disease Congenital hypotransferrinaemia – Life with Disease Waldenstrom’s macroglobulinaemia refractory – Basic Information Activated PI3 kinase delta syndrome – Basic Information Haemophagocytic lymphohistiocytosis – Basic Information IgA nephropathy – Diagnostics Cholangitis sclerosing – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Enfuvirtide Dapansutrile Magrolimab Sodium Iodide Somatropin Bi 690517 Tuvusertib Gremubamab Vo659 L-Histidine Hydrochloride Omp65 IPN01195 IMMUNOSTEM Alemtuzumab Tryptophan Abacavir Asciminib Zimberelimab Naproxen Elamipretide Trihydrochloride More therapies…

    Learn about Your Condition

    Hysterectomy Multiple sclerosis Delayed graft function Atrial fibrillation Hypocalcaemia Osteoporosis postmenopausal Congenital ureteric anomaly Corneal graft failure Endometrial cancer Diarrhoea Hypotransferrinaemia Magnetic resonance imaging Post procedural oedema Polyneuropathy Hypophosphatasia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Vaccine

  • Study on Stopping Dupilumab in Patients with Severe Asthma Who Have Been on the Drug for Over 3 Years

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Asthma
    Investigated Drugs:
    • Dupilumab
    France

  • A study of ruxolitinib as first treatment for children with haemophagocytic lymphohistiocytosis (HLH)

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Haemophagocytic lymphohistiocytosis
    Investigated Drugs:
    • Ruxolitinib
    France

  • Study on the Safety and Effectiveness of ARI0002h and Drug Combination for Newly Diagnosed Primary Plasma Cell Leukemia Patients

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • AUTOLOGOUS GENETICALLY MODIFIED T LYMPHOCYTES TRANSDUCED WITH LENTIVIRUS EXPRESSING CAR PROTEIN DIRECTED AGAINST BCMA
    • Lenalidomide
    • Cyclophosphamide
    Spain

  • Study on the Effectiveness and Safety of Deucravacitinib for Children and Teens with Juvenile Psoriatic Arthritis

    Recruiting

    3 1
    Investigated Drugs:
    • Deucravacitinib
    Bulgaria Czechia Germany Italy Romania Spain

  • Study of SGT-003 Gene Therapy for Safety and Tolerability in Walking Males with Duchenne Muscular Dystrophy

    Recruiting

    2 1 1
    Investigated Diseases:
    • Duchenne muscular dystrophy
    Investigated Drugs:
    • SGT-003
    Italy

  • Study on Seltorexant for Adults and Elderly with Major Depressive Disorder and Insomnia Symptoms

    Recruiting

    3 1
    Investigated Diseases:
    • Major depression
    Investigated Drugs:
    • SELTOREXANT
    Bulgaria Czechia Italy Poland Portugal Romania +3
Previous Page
1 … 244 245 246 247 248 … 1,649
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!